Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults - 20/08/11
, Gabriela Senti, MD a, Gabriel Schnetzler, MD a, Charles Wolf, MD a, Bettina M. Prinz Vavricka, MD a, Alma Fulurija, PhD b, Frank Hennecke, PhD b, Katja Sladko b, Gary T. Jennings, PhD b, Martin F. Bachmann, PhD b
Reprint requests: Thomas M. Kündig, MD, Dermatologische Klinik, Gloriastr. 31, 8091 Zürich, Switzerland.Zurich and Zurich-Schlieren, Switzerland
Abstract |
Background |
In mice, highly repetitive antigens, such as those present on bacterial or viral surfaces, efficiently cross-link B-cell receptors and therefore induce strong IgG responses. In this study we covalently coupled a synthetic 16-amino-acid sequence of the allergen Der p 1 to a virus-like particle derived from the bacteriophage Qβ (Qβ-Der p 1).
Objective |
We evaluated the safety and immunogenicity of Qβ-Der p 1 in human subjects and compared different doses and routes of immunization.
Methods |
In a phase I trial 24 healthy volunteers were randomly assigned to one of 4 treatment groups. Group 1 received 50 μg of Qβ-Der p 1 intramuscularly, group 2 received 50 μg of Qβ-Der p 1 subcutaneously, group 3 received 10 μg of Qβ-Der p 1 intramuscularly, and group 4 received 10 μg of Qβ-Der p 1 subcutaneously. Boosting immunizations with 10 μg were given after 1 and 3 months. Antibody titers were measured after 1, 3, 4, 6, 12, and 18 months.
Results |
The vaccine Qβ-Der p 1 was well tolerated. Significant IgG responses were observed 4 weeks after a single injection. Individuals receiving 50 μg of the vaccine had significantly higher IgG titers than those vaccinated with 10 μg. However, the route of immunization (subcutaneous vs intramuscular) had no effect. In the 50-μg dose group, strong antibody responses against Der p 1 with average titers of 1:2000 were obtained.
Conclusion |
Vaccination with a peptide antigen covalently coupled to highly repetitive virus-like particles represents an adjuvant-free means of rapidly inducing high antibody titers in human subjects.
Clinical implications |
Allergens coupled to virus-like particles can be used to enhance the efficiency of allergen-specific immunotherapy.
Le texte complet de cet article est disponible en PDF.Key words : Der p 1, virus-like particle, immunotherapy, clinical trial
Abbreviations used : GMP, Qβ-Der p 1, VLP
Plan
| Cytos Biotechnology AG entered into a sponsoring agreement with the University, covering the cost of laboratory analyses and the salary of 1 postdoctoral fellow independent of the trial outcome. Disclosure of potential conflict of interest: A. Fulurija, F. Hennecke, K. Sladko, G. T. Jennings, and M. F. Bachmann have stock in and are employed by Cytos Biotechnology. The rest of the authors have declared that they have no conflict of interest. |
Vol 117 - N° 6
P. 1470-1476 - juin 2006 Retour au numéro
Article précédent
- Bruton’s tyrosine kinase is not essential for LPS-induced activation of human monocytes
- Rebeca Pérez de Diego, Eduardo López-Granados, Maite Pozo, Cristina Rodríguez, Prado Sabina, Antonio Ferreira, Gumersindo Fontan, Maria Cruz García-Rodríguez, Susana Alemany
- Antigen selection in the IgE response of allergic and nonallergic individuals
- Isabell Dahlke, David J. Nott, John Ruhno, William A. Sewell, Andrew M. Collins
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?